ACM
HSTO

Anfield Capital Management’s Histogen Inc. Common Stock HSTO Stock Holding History

Anfield Capital Management’s Portfolio HSTO Stock Details HSTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1
Closed – – 419
2019
Q4 		$0 Buy
+1
New +$70 ﹤0.01% 413

Other funds holding HSTO

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return

Anfield Capital Management's HSTO Position: Q1 2020 in Review

Anfield Capital Management sold out of Histogen Inc. Common Stock (HSTO) in Q1 2020, closing a stake of 1 share.

Anfield Capital Management first reported a position in HSTO in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 27 funds tracked by Wall St. Rank hold HSTO as of Q1 2020.

  • Anfield Capital Management reported no remaining Histogen Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Anfield Capital Management sold 1 Histogen Inc. Common Stock share in Q1 2020.
  • Anfield Capital Management first reported a position in Histogen Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Anfield Capital Management's Histogen Inc. Common Stock position peaked at $0 in Q4 2019.
  • 27 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q1 2020.

Based on Anfield Capital Management's 13F filing for Q1 2020, filed 7 May 2020.